{"id":"W4378953442","doi":"10.3324/haematol.2023.283106","title":"Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib","year":2023,"lang":"en","type":"letter","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Italfarmaco; Astellas Pharma; Sierra Oncology; CTI Biopharma; Incyte; Jazz Pharmaceuticals; Gilead Sciences; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Oncology; Bone marrow","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001581936,0.000668329,0.002624571,0.0002531517,0.00005877356,0.00002558518,0.0001785021,0.0009840872,0.0007986449],"category_scores_gemma":[0.0002337336,0.0004076847,0.0005833924,0.0002782031,0.0001785976,0.0000511317,0.00008256871,0.0008686698,0.0007354069],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000630743,"about_ca_system_score_gemma":0.00009666492,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001034521,"about_ca_topic_score_gemma":0.00002619772,"domain_scores_codex":[0.9960693,0.0002387571,0.001254408,0.001015279,0.0008420745,0.0005801586],"domain_scores_gemma":[0.9969757,0.001279083,0.0004329657,0.0007266502,0.0003346632,0.0002509482],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001162874,0.0006664662,0.7378173,0.0002697852,0.0009901006,0.001559406,0.0002882774,5.409623e-7,5.490967e-7,0.000008040263,0.2564248,0.0008118342],"study_design_scores_gemma":[0.003360293,0.002132756,0.9565197,0.0008392329,0.0009696648,0.000006419935,0.0000295384,0.000001531953,0.0001180885,0.00009285043,0.03550692,0.0004229638],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"commentary","genre_scores_codex":[0.7545115,0.00005288137,0.00003090863,0.2402623,0.000418486,0.001874226,0.002497559,0.0001552252,0.00019696],"genre_scores_gemma":[0.4861771,0.0001712519,0.004089426,0.4985627,0.00111519,0.001844289,0.007300127,0.0001978293,0.0005421195],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.2683344,"threshold_uncertainty_score":0.9998375,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02960954829240236,"score_gpt":0.2987874401481742,"score_spread":0.2691778918557718,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}